Main Menu

In this study, the research explores the potential of PfCg4, a novel heat shock protein, as a candidate for a transmission-blocking malaria vaccine. By producing recombinant PfCg4 and conducting experiments demonstrating its susceptibility to antibody blockade in the mosquito midgut, the study presents evidence for its vaccine candidacy. This discovery holds promise for enhancing current efforts to combat malaria transmission and potentially offers cross-species transmission-blocking activity, given its similarity to the P. vivax Cg4 protein.

The document details the creation of an anti-idiotypic monoclonal antibody specifically targeting the PGT121 monoclonal antibody (mAb) used in HIV treatment, highlighting its potential in both therapeutic and preventative applications. To ensure the consistent quality and effectiveness of the PGT121 mAb, these anti-idiotypic antibodies are developed for monitoring purposes during clinical applications.

The collaborative effort between the Jarvis Laboratory at the University of Plymouth and Feldmann's laboratory led to the development and testing of a groundbreaking Cytomegalovirus (CMV)-based vaccine designed to express the Ebola virus glycoprotein. This innovative approach aimed to enhance Ebola virus-specific immunogenicity and efficacy. The Jarvis Laboratory was responsible for the initial design and construction of the vaccine prototype, while Feldmann's team conducted extensive testing for immunogenicity and efficacy using a nonhuman primate model.

Researchers have developed a groundbreaking influenza vaccine using a modular nanoparticle platform that displays hemagglutinin (HA) from various influenza strains on either separate or combined particles. Unlike traditional vaccines with limited efficacy due to antigenic mismatch, these novel nanoparticles can be customized to target seasonal strains, offering stronger immune responses and broader protection against multiple subtypes, including those not included in the annual vaccine formulation.

This technology involves the development of live attenuated vaccine candidates for respiratory syncytial virus (RSV), a significant cause of severe respiratory tract diseases, particularly in infants and young children. The approach focuses on relocating the NS1 and NS2 genes within the RSV genome to downstream positions, resulting in reduced transcription and expression. This gene-shifting strategy allows for controlled attenuation of the virus, avoiding over-attenuation seen with gene deletion. Combining gene shifts with other mutations fine-tunes the level of attenuation.

This technology presents a sophisticated two-step vaccination approach designed to provide comprehensive protection against filovirus infections, including Ebola and Marburg viruses. It involves administering a prime-boost vaccine sequence, employing replication-defective adenoviral serotype 26 (Ad26) as the priming agent and replication-defective adenoviral serotype 35 (Ad35) as the boosting agent. Both vectors are engineered to express the crucial filovirus envelope glycoprotein (GP), encompassing various strains of Ebolavirus (EBOV) and Marburg (MAR).

This technology includes a large panel of monoclonal antibodies (mAbs) against the spike glycoprotein, capable of recognizing intact SARS-CoV-2 virions with high affinity. Data to support SARS-CoV-2-specific binding include ELISA and label-free (biolayer interferometry) binding measurements using recombinant proteins, immunofluorescence in culture, immunofluorescence staining of tissue from infected patients, and virus neutralization assays.

This technology includes 8 novel strains of the species Streptococcus mitis, Streptococcus oralis, and Streptococcus infantis for vaccine or probiotic development. The capsular biosynthetic genes from each of these strains are highly related to pneumococcal counterparts encoding 5 capsular serotypes. All 8 of these non-pneumococcal strains were recovered from nasopharyngeal (NP) or oropharyngeal (OP) specimens.

This technology includes a compound, CDEU050, which has shown to have anti-Ebola virus activity in cell culture. CDEU050 is a novel small molecule, unrelated to any previously described inhibitor that blocks Ebola virus infection in cell culture.

This technology includes a Dengue-2 isolated virus for use as a cancer vaccine therapeutic.